3 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMOCompleted
To record and analyse the electrophysiological properties and differences of the human pituitary gland, i.e. the anterior lobe, posterior lobe and adenoma.
Approved WMOCompleted
To assess the prevalence of subclinical AF in obesity patients by using different contemporary AF-detection applications (primary objective). To investigate the potential role of GLS as a parameter to predict presence of AF in obesity patients (…